The majority of @entity1 with @entity1149 ( @entity1149 ) present with advanced disease, with targeted therapies providing some improvement in clinical outcomes. The @entity470 ( @entity470 ) @entity669 kinase (TK) plays an important role in the pathogenesis of @entity1149 . @entity669 kinase inhibitors (TKIs), which target the @entity470 TK domain, have proven to be an effective treatment strategy; however, @entity1 responses to treatment vary considerably. Therefore, the identification of @entity1 most likely to respond to treatment is essential to optimise the benefit of TKIs. Tumour-associated activating mutations in @entity470 can identify @entity1 with @entity1149 who are likely to have a good response to TKIs. Nonetheless, the majority of @entity1 relapse within a year of starting treatment. Studies of @entity5 at relapse have demonstrated expression of a @entity9513 mutation in exon 20 of the @entity470 TK domain in approximately 50% of cases. Although conferring resistance to reversible TKIs, these @entity1 may remain sensitive to new-generation irreversible/pan-erb inhibitors. A number of techniques have been employed for genotypic assessment of @entity5 -associated DNA to identify @entity470 mutations, each of which has advantages and disadvantages. This review presents an overview of the current methodologies used to identify such molecular markers. Recent developments in technology may make the monitoring of changes in @entity1 ' @entity5 genotypes easier in clinical practice, which may enable @entity1 ' treatment regimens to be tailored during the course of their disease, potentially leading to improved @entity1 outcomes.

The role of the molecular footprint of XXXX in tailoring treatment decisions in @entity1149 .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour'] @entity470 :: ('1956', 'Gene') :: ['EGFR', 'epidermal growth factor receptor'] @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small-cell lung cancer'] @entity669 :: ('CHEBI:18186', 'Chemical') :: ['Tyrosine', 'tyrosine'] @entity9513 :: ('p|SUB|T|790|M', 'ProteinMutation') :: ['T790M']
@entity470 :: (1956,Gene) :: ['EGFR']
